Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial
A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.
Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.
Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.
Adherence to a Mediterranean diet is inversely associated with the severity of anxiety and stress symptoms in older adults.
Hosts break down the FLOW trial, take a deep dive into secondary findings, and provide insight into how this alters the perception of the role for semaglutide in management of CKD in type 2 diabetes.
1. In this retrospective cohort study, exposure to antiseizure medications was associated with a higher incidence of autism spectrum disorder (ASD) compared to general population data. 2. Restricted to children born to mothers with epilepsy, valproate, but not topiramate and lamotrigine, was associated with an increased risk of ASD compared to no medication exposure. Evidence